buys ss, partridge e, black a, johnson cc, lamerato l, isaacs c, et al. effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial. jama 2011;305: 2295–303.

Sagot :

In the intervention group, 212 women (5.7 per 10,000 person-years) and 176 (4.7 per 10,000 person-years) received an ovarian cancer diagnosis (rate ratio [RR], 1.21; 95% confidence interval [CI], 0.99-1.48).

In the intervention group, there were 118 ovarian cancer-related deaths (3.1 per 10,000 person-years), compared to 100 in the standard care group (mortality RR, 1.18; 95% CI, 0.82-1.71).

1080 of the 3285 women who had false-positive test results underwent surgical follow-up, and 163 of them (15%) had at least one significant consequence.

Except for ovarian, colorectal, and lung cancer, there were 2924 deaths from other causes (76.6 per 10 000 person-years) in the intervention group and 2914 deaths (76.2 per 10 000 person-years)

Simultaneous screening with CA-125 and transvaginal ultrasound in comparison to standard treatment did not lower ovarian cancer mortality among women in the general US population. Complications were linked to diagnostic examination after a false-positive screening test result.

To learn more about ovarian cancer here:-

https://brainly.com/question/25637266?referrer=searchResults

#SPJ4